A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)

Name: A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)
Published: 2024
License: Public Domain

GlaxoSmithKline · 2024

ClinicalTrials.gov · Datasets · License: Public Domain · 2024

Open Source ↗

immunogenicity older-adults respiratory-syncytial-virus rsv safety

respiratory syncytial virus infections, rsv, respiratory syncytial virus, rsvpref3 oa vaccine, immunogenicity, safety, reactogenicity, at increased risk (air), older adults, respiratory syncytial virus lower respiratory tract disease (rsv-lrtd), interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)

Related documents